Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S1. Patient Characteristics.</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Qingsheng Xu (17078830) (author)
Autres auteurs:	Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Publié:	2025
Sujets:	Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires